August 13, 2025 — Instil Bio, Inc. (Nasdaq: TIL) reported its second quarter 2025 financial results and provided a corporate update. The company anticipates initiating a U.S. clinical trial of AXN-2510/IMM2510 before the end of 2025, following U.S. IND clearance. ImmuneOnco will present updated ‘2510 monotherapy data in squamous-NSCLC at IASLC’s 2025 World Conference on Lung Cancer.
Recent highlights include the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer in June, and the U.S. FDA’s clearance of the Investigational New Drug (IND) application for ‘2510 in July. Also in July, ImmuneOnco announced preliminary safety and efficacy data from a Phase 2 study of ‘2510 with chemotherapy for advanced non-small cell lung cancer patients in China.
As of June 30, 2025, Instil had $103.6 million in cash, cash equivalents, restricted cash, marketable securities, and long-term investments, expected to fund its operating plan beyond 2026.
Investor Relations:
1-972-499-3350
investorrelations@instilbio.com
Source: Instil Bio
